Compare Citius Pharmaceuticals Inc (CTXR) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs HSBC Holdings plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while HSBC Holdings plc trades at $103.8 (market cap $353.82B). The key difference: HSBC Holdings plc is far larger — about 18890.5× Citius Pharmaceuticals Inc's market cap, and HSBC Holdings plc pays a 3.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | HSBC | |
|---|---|---|
Market Cap | $18.73M | $353.82B |
Sector | Health | Technology |
52-Week High | $1.82 | $107.86 |
52-Week Low | $0.48 | $63.84 |
Enterprise Value | $14.95M | — |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
HSBC trades at $103.73, up 1.14% today, with a bullish technical signal from moving averages and support at $102. The stock shows strong fundamentals with a P/E of 14.76, net income margin of 34.54%, and ROE of 12.44%. Recent Q2 2026 earnings beat expectations, driven by 7% revenue growth and a $1 billion buyback announcement, reflecting robust banking and wealth management performance.
Outlook is positive due to earnings momentum and shareholder returns, but risks include China regulatory changes and a recent Citi downgrade. Analyst consensus is mixed with 38.1% buy ratings, suggesting cautious optimism amid a 40% year-to-date run, requiring monitoring of Asia exposure and interest rate trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
